Clinical Microbiology and Infection | 2021

Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort

 
 
 
 
 
 
 

Abstract


\n Objectives\n Persistent COVID-19 symptoms have been reported up to 3\xa0months after hospital discharge. Little is known on the frequency and the nature of persistent symptoms beyond 3\xa0months. Here we have assessed, in the longitudinal prospective French COVID-19 cohort, symptoms that persisted 6\xa0months after admission for COVID-19.\n \n Methods\n Hospitalized patients with virologically confirmed COVID-19 were enrolled. Follow-up was planned with a physician s visit at month (M)3 and M6 after admission. Associations between persistence of symptoms at M6 and clinical characteristics at admission were assessed through bivariate and multivariate logistic regression.\n \n Results\n M6 data were available for 1137\xa0participants. Median age was 61\xa0years (IQR 51–71) and 288 (29%, 95% CI 26–32%) were admitted to intensive care unit (ICU) during the acute phase. Six hundred and fifty-five (68%, 95% CI 65–71%) and 639 (60%, 95% CI 57–63%) participants had at least one symptom at M3 and M6 visit, respectively, mostly fatigue, dyspnoea, joint pain and myalgia. At M6, 255 (24%, 95% CI 21–27%) of participants had three or more persistent symptoms. The presence of three or more symptoms at M6 was independently associated with female gender (adjusted odds ratio (aOR) 2.40, 95% CI 1.75–3.30), having three or more symptoms at admission (aOR 2.04, 95% CI 1.45–2.89) and ICU admission/transfer during acute phase (aOR 1.55, 95% CI 1.09–2.18), but not significantly with age or having two or more comorbidities. One hundred and twenty-five (29%, 95% CI 25–34%) of those who initially had a professional occupation were not back to work at M6.\n \n Discussion\n A fourth of individuals admitted to hospital for COVID-19 still had three or more persistent symptoms at M6. Longitudinal follow-up of individuals with severe COVID-19 is warranted to better understand the pathophysiology underlying this long-term persistence.\n

Volume 27
Pages 1041.e1 - 1041.e4
DOI 10.1016/j.cmi.2021.03.012
Language English
Journal Clinical Microbiology and Infection

Full Text